New treatment option recommended for patients with melanoma

The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Keytruda (pembrolizumab).

It is recommended as monotherapy for the treatment of adult patients with advanced melanoma that cannot be surgically removed or where the cancer has spread to other parts of the body (unresectable or metastatic melanoma). Melanoma is the most aggressive form of skin cancer and the leading cause of death from skin disease. The main risk factor for developing melanoma is ultraviolet (UV) light and intermittent exposure to the sun.

Original source


Register for receiving PharmaAround news, register for PharmAround events.
Continue registration